Mark J. Tebbe

Mark J. Tebbe

Chief Tech/Sci/R&D Officer bij Newco (Canada)

Health Technology
Finance
Consumer Services

Profiel

Mark is CTO of Matchpoint Therapeutics.
Formerly Mark was Co-Founder and CTO of Quench Bio and before that was VP, Head of Drug Discovery at Quartet Medicine.
Mark has >23 years of experience in drug discovery and development and is a co-inventor of Incivek (Telaprevir), an HCV protease inhibitor.
He was previously VP of Medicinal and Computational Chemistry at Forma Therapeutics where he focused on small molecule cancer therapeutics.
Prior to that, Mark held positions of increasing responsibility during his 16-year career at Eli Lilly including head of chemistry and Global Head of Operations for the discovery chemistry group.
He obtained his Ph.D.
in organic chemistry from Stanford University and his undergraduate degree from the University of Notre Dame.

Actieve functies van Mark J. Tebbe

BedrijvenFunctieBegin
Consultant / Advisor 01-11-2017
Chief Tech/Sci/R&D Officer 01-06-2023
Alle actieve functies van Mark J. Tebbe

Eerdere bekende functies van Mark J. Tebbe

BedrijvenFunctieEinde
Chief Tech/Sci/R&D Officer 01-03-2023
Chairman 01-12-2019
Consultant / Advisor 01-06-2010
Founder -
Corporate Officer/Principal -
Ervaring van Mark J. Tebbe in detail bekijken

Opleiding van Mark J. Tebbe

University of Notre Dame Undergraduate Degree
Stanford University Doctorate Degree

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van Mark J. Tebbe in detail bekijken

Connecties

86

Eerstegraads connecties

10

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Persoonlijk netwerk weergeven

Verwante bedrijven

Bedrijven in privébezit8

Health Technology

Finance

Commercial Services

Health Technology

Finance

Health Technology

Health Technology

Finance

Zie bedrijfsconnecties
  1. Beurs
  2. Insiders
  3. Mark J. Tebbe